$15.73-0.64 (-3.91%)
SANUWAVE Health, Inc.
SANUWAVE Health, Inc. in the Healthcare sector is trading at $15.73. The stock is currently near its 52-week low of $15.57, remaining 47.1% below its 200-day moving average. Technical signals show neutral RSI of 42 and bearish MACD signal, explaining why SNWV maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
SANUWAVE Health, Inc. operates as a medical device company in the United States and internationally. It focuses on the commercialization of regenerative medicines through noninvasive ultrasound or shockwaves to produce a biological response promoting...
Sanuwave Health (SNWV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The latest analyst update on SANUWAVE Health centers on a revised price target that is now set $6 lower, even as the fair value anchor holds at $43.5. Analysts who are constructive on the story view this change as a reset that lines expectations up more tightly with current assumptions. More cautious voices see it as a signal to reassess growth and execution risk. As you read on, you will see what this shift could mean for your own view of the stock and how to follow the evolving narrative...
Michigan-based investment advisor Cedar Grove Capital Management recently released its first quarter 2026 investor letter. A copy of the letter can be downloaded here. Cedar Grove Capital Management’s Multi-Strategy Composite posted a -23.0% net return since inception, compared to -5.6% for the Russell 2000, -5.9% for the Russell Microcap, and -5.5% for the S&P 500. […]
SANUWAVE Health’s revised price target, now reduced by $6, has sharpened the focus on what analysts see as a more cautious stance on the story. That reset is tied to updated views on how revenue and profitability might support the valuation investors are prepared to pay, with research teams weighing both potential upside and execution risk. As you read on, you will see what is driving this evolving narrative and how to track the key milestones that could shape it from here. Stay updated as...
SANUWAVE Health is back in focus after an analyst fair value estimate reset from US$55.00 to US$43.50, a reduction of about US$11.50 per share. Bulls view the new US$43.50 target as still leaving room for upside if the company delivers on updated assumptions. Bears see the lower mark as a signal that earlier expectations may have been too optimistic. As you read on, you will see how to track these shifting views and what they might mean for your own research process around SANUWAVE...